Navigation Links
Regeneron Announces Settlement of Patent Litigation with Genentech for U.S. Ophthalmic Sales of EYLEA™ (aflibercept) Injection
Date:1/3/2012

TARRYTOWN, N.Y, Jan. 3, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the Company has entered into a non-exclusive license and partial settlement agreement (Agreement) with Genentech, Inc., a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) relating to U.S. ophthalmic sales of EYLEA™ (aflibercept) Injection.

Regeneron received a non-exclusive license to certain patents relating to VEGF receptor proteins, known as the Davis-Smyth patents, and other technology patents.  The Davis-Smyth patents are the subject of patent litigation between Regeneron and Genentech now pending in the United States District Court, Southern District of New York.  Patent litigation is continuing with respect to matters not covered by the Agreement.

Under the terms of the Agreement, Regeneron will make payments to Genentech based on U.S. sales of EYLEA through May 7, 2016.  Regeneron will pay $60 million upon cumulative U.S. sales of EYLEA reaching $400 million.  Regeneron will also pay royalties of 4.75% on cumulative U.S sales of EYLEA between $400 million and $3 billion and 5.5% on any cumulative U.S sales of EYLEA over $3 billion.

About Regeneron PharmaceuticalsRegeneron is a fully integrated biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.  Regeneron markets two products, ARCALYST® (rilonacept) Injection For Subcutaneous Use and EYLEA™ (aflibercept) Injection.  Regeneron also has completed several Phase 3 studies and is conducting an additional Phase 3 clinical trial for the product candidate ZALTRAP® (aflibercept) Concentrate for Intravenous Infusion.  Additional therapeutic candidates developed from proprietary Regeneron technologies for creating fully human mo
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Regeneron to Host Conference Call on January 3 at 8:30 a.m. Eastern Time to Discuss Ongoing Patent Litigation
2. Regeneron Announces Presentation Time Change at the 2011 Deutsche Bank BioFEST
3. Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review
4. Rockefeller University President Marc Tessier-Lavigne Elected to Regeneron Board of Directors
5. Regeneron Announces FDA Approval of EYLEA™ (aflibercept) Injection for the Treatment of Wet Age-Related Macular Degeneration
6. Sanofi and Regeneron Report Positive Preliminary Phase 2 Program Results for Anti-PCSK9 Antibody in Hypercholesterolemia
7. Regeneron Pharmaceuticals Announces Pricing of Offering of Convertible Senior Notes due October 1, 2016
8. Regeneron Ranked by Science Magazine as the #2 Employer in the Global Biopharmaceutical Industry
9. Regeneron Announces Clinical Presentations at ASRS 2011 Annual Meeting
10. Regeneron Reports Second Quarter 2011 Financial and Operating Results
11. Sanofi and Regeneron Report Positive Phase 2b Trial Results with Sarilumab in Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... June 19, 2013 Today MedeAnalytics, a ... the next-generation of its Employer Group and ... plans to provide their employer groups an intuitive ... medical and prescription drug claims, network utilization, and ... http://photos.prnewswire.com/prnh/20100621/SF23660LOGO ) "Employer Group and ...
(Date:6/19/2013)... FRANCISCO , June 19, 2013  It may seem ... possible cure for breast cancer. But these were two of ... Society,s 95 th Annual Meeting & Expo that just ... some are saying this focus by some of the top ... our culture,s obsession with new research that can not only ...
(Date:6/18/2013)...  Intercept Pharmaceuticals, Inc.  (NASDAQ: ICPT ), ... and commercialization of novel bile acid therapeutics to treat ... underwritten public offering of 1,730,000 shares of its common ... share.  In addition, Intercept has granted the underwriters a ... shares of common stock. All of the ...
Breaking Medicine Technology:MedeAnalytics Introduces Next-Generation Employer Group and Individual Business Analytics Solution 2"Miracle" Breast Cancer Drug and "Youth Hormone" Pill Steal Show at Prestigious Endocrine Society Conference 2"Miracle" Breast Cancer Drug and "Youth Hormone" Pill Steal Show at Prestigious Endocrine Society Conference 3"Miracle" Breast Cancer Drug and "Youth Hormone" Pill Steal Show at Prestigious Endocrine Society Conference 4Intercept Pharmaceuticals Announces Pricing of Public Offering of Common Stock 2
... Aug. 27 Pharmacopeia,(Nasdaq: PCOP ), ... of novel,small molecule therapeutics, announced today that ... Special Program for Research and Training,in Tropical ... novel antimalarial,agents. Pharmacopeia will receive funding to ...
... have started a phase IIa clinical trial designed to ... C viral infection, one,of the toughest infectious diseases in ... which works as a,regulator of the body,s immune response, ... hepatitis C viral infection. "The drugs currently in ...
Cached Medicine Technology:Drug in New Hepatitis C Clinical Trial 2
(Date:6/19/2013)... are increasingly common on college campuses, but are ... up"? A new study by researchers with The ... published online by the Archives of Sexual ... behaviors associated with sexual hookups, particularly among first-year ... negative emotional and physical health outcomes as a ...
(Date:6/19/2013)... 19, 2013 The Movement ... neurosurgeons, psychiatrists and urologists with specialists in physical ... works with patients and their family members to ... of life. Patients also have the opportunity to ... research. , “Movement disorders can be relentlessly progressive ...
(Date:6/19/2013)... Could drugs that block the body,s system for repairing ... to health? As unlikely as it may seem, those ... and breast cancers driven by a mutation in BRCA, ... revealed she carries the mutation. The compounds, termed PARP ... the current edition of Chemical & Engineering News ...
(Date:6/19/2013)... Research Triangle Park, NC (PRWEB) June 19, 2013 ... Entegrion , Inc., announced organizational changes to ... Chairman John B. Mowell said, “To support the ... of Directors has made changes to the Company’s ... advisors.” , The Company announced that ...
(Date:6/19/2013)... Moffitt Cancer Center and colleagues at Louisiana State University ... that require immediate therapy. It relies on understanding the ... is to better predict a prostate cancer,s aggressiveness to ... published in the online journal PLOS ONE ... accounts for 20 percent of all cancers and 9 ...
Breaking Medicine News(10 mins):Health News:Why are some college students more likely to 'hook up'? 2Health News:Abington Memorial Hospital’s Neurosciences Institute Opens Movement Disorders Center 2Health News:Entegrion Announces Organizational Changes to Support Advanced Product Development 2Health News:Entegrion Announces Organizational Changes to Support Advanced Product Development 3Health News:Moffitt Cancer Center researchers identify genetic variants predicting aggressive prostate cancers 2
... University Melvin and Bren Simon Cancer Center will ... health care solutions. WellPoint announced plans in ... to help improve patient care and support physicians ... personalized treatment decisions possible. It is estimated that ...
... the screw. That,s just a part of life for people, ... osteogenesis, a method to correct bone deformities that leave one ... University undergraduates has invented a device they hope will make ... Hospital for Children in Houston, the students came up with ...
... April 23 (HealthDay News) -- It goes without saying that ... they can also be very expensive, an expert warns. ... a person bitten by a venomous snake, said Jill Heatley, ... in College Station. The total cost includes hospitalization, which ...
... SAGE Launch Clinical Psychological Science ,Association for Psychological ... Angeles, CA (April 23, 2012) The Association for ... Clinical Psychological Science , a new peer-reviewed journal focused ... venue for cutting-edge research across a wide range of ...
... and American Associations for Dental Research have published ... articles, titled "Hypoplasia-Associated Severe Early Childhood Caries ... York University College of Dentistry) and "Deciduous Molar ... Elfrink, Academic Centre for Dentistry, Amsterdam) discuss the ...
... Guy, M.D., professor of ophthalmology at Bascom Palmer Eye ... Medicine, has pioneered a novel technological treatment for Leber ... causes rapid, permanent, and bilateral loss of vision in ... Genetic mutations in the mitochondria (part of the ...
Cached Medicine News:Health News:IU Simon Cancer Center joins WellPoint in developing health care solutions 2Health News:IU Simon Cancer Center joins WellPoint in developing health care solutions 3Health News:Rice University student engineers automate limb lengthening for kids 2Health News:Rice University student engineers automate limb lengthening for kids 3Health News:Cost of Snakebite Therapy May Squeeze Victims' Wallets 2Health News:Association for Psychological Science, SAGE launch Clinical Psychological Science 2Health News:IADR/AADR publish studies on severe early childhood caries - proposes new classification 2Health News:IADR/AADR publish studies on severe early childhood caries - proposes new classification 3Health News:Bascom Palmer Eye Institute announces breakthrough for degenerative vision disorder 2
... Wampole Laboratories offers a comprehensive line of ... serum and urine in convenient one-step stick ... 2 testing options. Clearview Easy HCG is ... convenient stick format. Clearview HCG II ...
The BioCheck hCG ELISA is intended for the quantitative determination of human chorionic gonadotropin (hCG) concentration in human serum. The assay is for use in the early diagnosis of pregnancy in a...
... preparation of whole blood is mixed continuously ... cation-exchange resin. During this time, HbAo binds ... a filter separator is used to remove ... contains glycohemoglobin. The percent glycohemoglobin is determined ...
The BioCheck Ferritin ELISA is intended for the quantitative determination of ferritin in human serum. This assay is to be used in the diagnosis of diseases affecting iron metabolism....
Medicine Products: